Ranking based on simulations for BCVA changes from baseline at 6 months
| Drug | Rank 1 | Rank 2 | Rank 3 | Rank 4 | Rank 5 | Rank 6 |
| Aflibercept | 0.34 | 0.45 | 0.16 | 0.04 | 0.01 | 0.00 |
| Bevacizumab | 0.54 | 0.28 | 0.14 | 0.02 | 0.01 | 0.00 |
| Dexamethasone | 0.01 | 0.01 | 0.02 | 0.07 | 0.19 | 0.70 |
| Ranibizumab | 0.10 | 0.21 | 0.53 | 0.14 | 0.02 | 0.00 |
| Sham/Placebo | 0.00 | 0.00 | 0.01 | 0.06 | 0.68 | 0.25 |
| Triamcinolone | 0.01 | 0.05 | 0.14 | 0.66 | 0.10 | 0.04 |
95% CrI, 95% credible intervals; BCVA, best-corrected visual acuity; CRT, central retinal thickness.